|
|
There are 7 internationally-leading laboratories contribute strength to novel biomaterials design and development, focusing on bioactivity, cell-associated environmental responsiveness, and controllable or inducible intrinsic porosity. The team has experience in driving entirely new biomaterials from the laboratory drawing board to clinical testing and market entry.
|
|
|
There are 5 exceptionally strong laboratories in angiogenesis and lymphangiogenesis provide bring state-of-the-art angiogenesis science into the project’s realm, having experiences ranging from fundamental angiogenesis biology to clinical trials.
|
|
|
2 outstanding laboratories bring complementary methods of imaging and analysis of complex angiogenic Structures in 3D into the project to quantitatively compare approaches. |
9 world-leading laboratories focus on clinically relevant tissue
engineering
applications demanding
angiogenic responses, critically testing the
consortium’s approach in bone, skin, cardiac muscle,
skeletal muscle, and
peripheral nerve repair. The team has experience ranging from basic
molecular and cellular studies to animal and
clinical investigations.
AngioScaff’s 11 industrial partners are integral to the entire research and
development plan and
provide a route for dissemination of scientific and
technological developments.
The consortium is pleased to have most of
Europe’s major and rising players in tissue engineering and biomaterials.
